Brad Rovin, MD

The Ohio State University
Columbus, OH, United States

Brad H. Rovin, MD, FACP, FASN
Dr. Brad H. Rovin is the Lee A. Hebert Professor of Nephrology at the Ohio State University Wexner Medical Center. He is the Division Director of Nephrology and Medical Director of the Ohio State University Clinical Research Management Organization. Dr. Rovin conducts translational research on autoimmune glomerular diseases and applies these studies to clinical trial development and design for investigator-initiated and industry-sponsored trials of novel therapeutics.

Presentation(s):

• 0784: Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial

  Sunday, November 12, 2023
  2:45 PM – 2:55 PM PT

  Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia: Consultant (Ongoing), Grant/Research Support (Ongoing); Biogen: Consultant (Ongoing); F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Genentech: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Novartis: Consultant (Ongoing)

• Diagnostic Challenges and Monitoring with Current Noninvasive Biomarkers in ANCA-Associated Glomerulonephritis and Lupus Nephritis

  Tuesday, November 14, 2023
  11:00 AM – 11:15 AM PT

  Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia: Consultant (Ongoing), Grant/Research Support (Ongoing); Biogen: Consultant (Ongoing); F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Genentech: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Novartis: Consultant (Ongoing)

• 235: Exploring New Frontiers: CAR T Cell Therapy in Autoimmune Diseases

  Tuesday, November 14, 2023
  6:00 PM – 8:00 PM PT

  Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Aurinia: Consultant (Ongoing), Grant/Research Support (Ongoing); Biogen: Consultant (Ongoing); F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Genentech: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Novartis: Consultant (Ongoing)